Analysts Offer Insights on Healthcare Companies: miRagen Therapeutics Inc (NASDAQ: MGEN) and Edwards Lifesciences (NYSE: EW)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on miRagen Therapeutics Inc (NASDAQ: MGEN) and Edwards Lifesciences (NYSE: EW) with bullish sentiments.

miRagen Therapeutics Inc (NASDAQ: MGEN)

B.Riley FBR analyst Madhu Kumar reiterated a Buy rating on miRagen Therapeutics Inc (NASDAQ: MGEN) today and set a price target of $15.50. The company’s shares opened today at $8.06.

Kumar said:

“This morning, 2/2, miRagen Therapeutics announced additional data from the Phase I study of lead asset MRG-106 for mycosis fungoides (MF) at the T-Cell Lymphoma Forum. In particular, 4/5 (80%) of patients treated with a 300 mg intravenous (IV) MRG-106, the expected Phase II dose of the drug, achieved a 50% reduction in the modified Severity Weighted Assessment Tool (mSWAT) score, which we consider the key clinical endpoint in MF. We view this as a material positive, as MRG-106 represents $11.13 (72%) of our 12-month price target, and thus reiterate our Buy rating for miRagen.”

According to TipRanks.com, Kumar is a top 100 analyst with an average return of 49.9% and a 71.2% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Iovance Biotherapeutics Inc.

miRagen Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $15.83.

Edwards Lifesciences (NYSE: EW)

Northland Securities analyst Suraj Kalia assigned a Buy rating to Edwards Lifesciences (NYSE: EW) today and set a price target of $120. The company’s shares opened today at $133.76, close to its 52-week high of $137.95.

Kalia noted:

“We maintain our constructive stance on this name. Key Points US TAVI sales of $327M was up 22% y/y on as-reported basis, OUS TAVI revs excluding stocking order in Germany) @ $192M was up 16% y/y. F/X impact was 200 bps favorably.”

According to TipRanks.com, Kalia is a 4-star analyst with an average return of 7.3% and a 54.5% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Apollo Endosurgery Inc.

Currently, the analyst consensus on Edwards Lifesciences is Strong Buy and the average price target is $146, representing a 9.2% upside.

In a report issued on January 31, SunTrust Robinson also reiterated a Buy rating on the stock with a $150 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.